manilatimes6h
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential ...
news.stocktradersdaily1d
Trading (BBIO) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
bovnews2d
The BBIO Stock Mystery: Why Did BBIO Plunge Today?
On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
Research Analysts Set Expectations for BBIO FY2027 Earnings
Equities research analysts at Leerink Partnrs cut their FY2027 EPS estimates for shares of BridgeBio Pharma in a research ...
BridgeBio Pharma: FDA Endorsement and Stable Price Target Bolster Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
Business Insider6d
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...